标题
Emerging protein kinase inhibitors for the treatment of multiple myeloma
作者
关键词
-
出版物
EXPERT OPINION ON EMERGING DRUGS
Volume -, Issue -, Pages 1-20
出版商
Informa UK Limited
发表日期
2019-07-22
DOI
10.1080/14728214.2019.1647165
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial
- (2018) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Pharmacologic inhibition of AKT leads to cell death in relapsed multiple myeloma
- (2018) In-Sung Song et al. CANCER LETTERS
- Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity on multiple myeloma bone disease
- (2018) Joséphine Muller et al. HAEMATOLOGICA
- Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance
- (2018) Sabrina Manni et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Repurposing of the CDK inhibitor PHA-767491 as a NRF2 inhibitor drug candidate for cancer therapy via redox modulation
- (2018) Hsiu-Yu Liu et al. INVESTIGATIONAL NEW DRUGS
- Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways
- (2018) Yan Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018
- (2018) Shaji K. Kumar et al. Journal of the National Comprehensive Cancer Network
- Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma
- (2018) Ajai Chari et al. LEUKEMIA & LYMPHOMA
- ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo
- (2018) Darren L. Lath et al. PLoS One
- Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity on multiple myeloma bone disease
- (2018) Joséphine Muller et al. HAEMATOLOGICA
- The therapeutic potential of cell cycle targeting in multiple myeloma
- (2017) Anke Maes et al. Oncotarget
- A phase I study of XL228, a multitargeted protein kinase inhibitor, in patients (pts) with solid tumors or multiple myeloma.
- (2017) D. C. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia
- (2016) Irene M. Ghobrial et al. AMERICAN JOURNAL OF HEMATOLOGY
- Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma
- (2016) N. Lendvai et al. BLOOD
- Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma
- (2016) D. Perumal et al. CANCER RESEARCH
- Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation
- (2016) Ulrich J.M. Mey et al. HEMATOLOGICAL ONCOLOGY
- Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- NF-κB dysregulation in multiple myeloma
- (2016) Geoffrey M. Matthews et al. SEMINARS IN CANCER BIOLOGY
- A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma
- (2015) Allison Rosenthal et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma
- (2015) Johanna C. Bendell et al. CANCER
- Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models
- (2015) Fu-Ming Zi et al. CANCER LETTERS
- A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma
- (2015) B. Holkova et al. CLINICAL CANCER RESEARCH
- Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation
- (2015) Christof Scheid et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?
- (2015) Manuela Gambella et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study
- (2015) A. Gunther et al. HAEMATOLOGICA
- A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191
- (2015) Annette E. Hay et al. LEUKEMIA & LYMPHOMA
- Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma
- (2015) Ruben Niesvizky et al. LEUKEMIA & LYMPHOMA
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the Pim kinases in multiple myeloma
- (2015) N A Keane et al. Blood Cancer Journal
- Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study
- (2015) A. Gunther et al. HAEMATOLOGICA
- The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies
- (2015) Hae J. Chon et al. Frontiers in Pharmacology
- Bruton’s tyrosine kinase: oncotarget in myeloma
- (2015) Yu-Tzu Tai et al. Oncotarget
- RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2
- (2014) Y. X. Zhu et al. BLOOD
- Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma
- (2014) S. K. Kumar et al. BLOOD
- The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
- (2014) A. Spencer et al. BLOOD
- The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma
- (2014) W Wu et al. BRITISH JOURNAL OF CANCER
- Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide
- (2014) Andrew J. Yee et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
- (2014) Anthony W. Tolcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition
- (2014) N. Mimura et al. CANCER RESEARCH
- Vemurafenib Response in 2 Patients With Posttransplant Refractory BRAF V600E–Mutated Multiple Myeloma
- (2014) J.P. Sharman et al. Clinical Lymphoma Myeloma & Leukemia
- The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma
- (2014) Jie Li et al. CURRENT PHARMACEUTICAL DESIGN
- Current assessment of polo-like kinases as anti-tumor drug targets
- (2014) Sandra N Craig et al. Expert Opinion on Drug Discovery
- AKT as a therapeutic target in multiple myeloma
- (2014) Niamh A Keane et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- A novel Bruton’s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity
- (2014) H Eda et al. LEUKEMIA
- Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2
- (2014) S Manni et al. LEUKEMIA
- Maternal Embryonic Leucine Zipper Kinase: Key Kinase for Stem Cell Phenotype in Glioma and Other Cancers
- (2014) R. Ganguly et al. MOLECULAR CANCER THERAPEUTICS
- Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma
- (2014) D. Cirstea et al. MOLECULAR CANCER THERAPEUTICS
- A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434
- (2014) Gordan Srkalovic et al. Cancer Medicine
- The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication
- (2013) Mathias Rask-Andersen et al. Annual Review of Pharmacology and Toxicology
- Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation
- (2013) J. Lu et al. BLOOD
- A phase I trial of flavopiridol in relapsed multiple myeloma
- (2013) Craig C. Hofmeister et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor
- (2013) S. Alvarez-Fernandez et al. CLINICAL CANCER RESEARCH
- Sorafenib in patients with refractory or recurrent multiple myeloma
- (2013) Anna Yordanova et al. HEMATOLOGICAL ONCOLOGY
- Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies
- (2013) Shaji K. Kumar et al. INVESTIGATIONAL NEW DRUGS
- Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies
- (2013) M Roschewski et al. LEUKEMIA
- Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs
- (2013) D Cirstea et al. LEUKEMIA
- Bruton's tyrosine kinase: potential target in human multiple myeloma
- (2013) Ying Liu et al. LEUKEMIA & LYMPHOMA
- A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma
- (2013) Eric Jourdan et al. LEUKEMIA & LYMPHOMA
- Endoplasmic Reticulum Stress and the Unfolded Protein Response: Targeting the Achilles Heel of Multiple Myeloma
- (2013) L. Vincenz et al. MOLECULAR CANCER THERAPEUTICS
- Scytonemin inhibits cell proliferation and arrests cell cycle through downregulating Plk1 activity in multiple myeloma cells
- (2013) Guojun Zhang et al. TUMOR BIOLOGY
- Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models
- (2013) Alessandro Natoni et al. Cancers
- AURORA KINASES: STRUCTURE, FUNCTIONS AND THEIR ASSOCIATION WITH CANCER
- (2012) Madhu Kollareddy et al. BIOMEDICAL PAPERS-OLOMOUC
- Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study
- (2012) Andrzej J. Jakubowiak et al. BRITISH JOURNAL OF HAEMATOLOGY
- p38 MAPK in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction
- (2012) J. He et al. CANCER RESEARCH
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Protein Kinase CK2 Protects Multiple Myeloma Cells from ER Stress-Induced Apoptosis and from the Cytotoxic Effect of HSP90 Inhibition through Regulation of the Unfolded Protein Response
- (2012) S. Manni et al. CLINICAL CANCER RESEARCH
- Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity
- (2012) Paul G Richardson et al. Expert Opinion on Drug Metabolism & Toxicology
- Novel players in multiple myeloma pathogenesis: Role of protein kinases CK2 and GSK3
- (2012) Francesco Piazza et al. LEUKEMIA RESEARCH
- Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance
- (2012) V Chell et al. ONCOGENE
- Anti-Myeloma Activity of Akt Inhibition Is Linked to the Activation Status of PI3K/Akt and MEK/ERK Pathway
- (2012) Vijay Ramakrishnan et al. PLoS One
- A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma
- (2011) Irene M. Ghobrial et al. AMERICAN JOURNAL OF HEMATOLOGY
- RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5
- (2011) Y. X. Zhu et al. BLOOD
- The potential role of Aurora kinase inhibitors in haematological malignancies
- (2011) Sherif S. Farag BRITISH JOURNAL OF HAEMATOLOGY
- Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications
- (2011) Douglas W. McMillin et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms
- (2011) B. Holkova et al. CLINICAL CANCER RESEARCH
- Combination of Farnesyltransferase and Akt Inhibitors Is Synergistic in Breast Cancer Cells and Causes Significant Breast Tumor Regression in ErbB2 Transgenic Mice
- (2011) M. E. Balasis et al. CLINICAL CANCER RESEARCH
- HSP90 Inhibitors as Therapy for Multiple Myeloma
- (2011) Saad Z. Usmani et al. Clinical Lymphoma Myeloma & Leukemia
- The Pim Kinases: New Targets for Drug Development
- (2011) Ronan Swords et al. CURRENT DRUG TARGETS
- Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial
- (2011) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide–CCI-779 Interaction via P-Glycoprotein
- (2011) Craig C. Hofmeister et al. JOURNAL OF CLINICAL ONCOLOGY
- Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study
- (2011) Irene M Ghobrial et al. LANCET ONCOLOGY
- Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma
- (2011) Robert P. Evans et al. LEUKEMIA RESEARCH
- Physiological Relevance of Cell Cycle Kinases
- (2011) Marcos Malumbres PHYSIOLOGICAL REVIEWS
- Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor
- (2010) B. Hoang et al. BLOOD
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma
- (2010) M. V. Mateos et al. CLINICAL CANCER RESEARCH
- The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma
- (2010) Helen J. Stewart et al. EXPERIMENTAL HEMATOLOGY
- p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells
- (2010) Sumin Kang et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma
- (2010) Wei-Gang Tong et al. JOURNAL OF CLINICAL ONCOLOGY
- Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation
- (2010) A C Sprynski et al. LEUKEMIA
- Efficacy and tolerability of PTK787/ZK 222584 in a phase II study of post-transplant maintenance therapy in patients with multiple myeloma following high-dose chemotherapy and autologous stem cell transplant
- (2010) Ravi Vij et al. LEUKEMIA & LYMPHOMA
- MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
- (2010) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- TGF-β Inhibition Restores Terminal Osteoblast Differentiation to Suppress Myeloma Growth
- (2010) Kyoko Takeuchi et al. PLoS One
- The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor
- (2009) Anne Catherine Sprynski et al. BLOOD
- Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034): Table 1
- (2009) H. Miles Prince et al. BLOOD
- Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens
- (2009) S. Kumar et al. BLOOD
- Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6
- (2009) R. E. Tiedemann et al. BLOOD
- Cdc7 kinase – A new target for drug development
- (2009) Ronan Swords et al. EUROPEAN JOURNAL OF CANCER
- Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma
- (2009) N Raje et al. LEUKEMIA
- Dasatinib in relapsed or plateau-phase multiple myeloma
- (2009) Tanya M. Wildes et al. LEUKEMIA & LYMPHOMA
- Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma
- (2009) Sherif S. Farag et al. LEUKEMIA RESEARCH
- p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications
- (2008) Kenji Ishitsuka et al. BRITISH JOURNAL OF HAEMATOLOGY
- Aurora Kinases as Anticancer Drug Targets
- (2008) O. Gautschi et al. CLINICAL CANCER RESEARCH
- Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma
- (2008) Martha Q. Lacy et al. JOURNAL OF CLINICAL ONCOLOGY
- First Cdc7 Kinase Inhibitors: Pyrrolopyridinones as Potent and Orally Active Antitumor Agents. 2. Lead Discovery†
- (2008) Maria Menichincheri et al. JOURNAL OF MEDICINAL CHEMISTRY
- The oral protein-kinase Cβinhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines
- (2008) Antonino Neri et al. LEUKEMIA & LYMPHOMA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More